Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples